CTS 2026: What to Expect in Las Vegas

Arshad M. Khanani, MD, previews this year’s Clinical Trials at the Summit meeting, highlighting new clinical trial data, expert panels discussing a variety of topics, and a keynote by the former director of the FDA’s ophthalmic devices division.

By Arshad M. Khanani, MD, MA, FASRS

FDA Veteran Shares Insights on Trial Design and Endpoints

Former FDA ophthalmology leader Wiley A. Chambers, MD, discusses pivotal studies, safety databases, and regulatory expectations for retinal therapies.

By Wiley A. Chambers, MD, Diana V. Do, MD

How to Choose the Right CRO

During a panel discussion at Clinical Trials at the Summit, representatives of sponsors and CROs discussed experience, staffing, costs, and the factors that drive trial performance.

By Jim Gallagher, senior managing editor

LensOne Heads Toward Pivotal Trial

At Clinical Trials at the Summit 2026, Frank Brodie, MD, MBA, reviewed clinical findings for the prosthetic capsular bag and outlined plans for the GOLDEN GATE study.

By Frank Brodie, MD, MBA, Diana V. Do, MD

SPECTRA Data Support 4D-150 in DME

Anat Loewenstein, MD, MHA, discusses previously presented findings from the SPECTRA trial at Clinical Trials at the Summit 2026.

By Anat Loewenstein, MD, MHA, Diana V. Do, MD

Four-Year OPTIC Data Highlight Durability of Ixo-vec

Carl Danzig, MD, reviews long-term outcomes from the OPTIC trial, including an 86% annualized reduction in anti-VEGF injections through year 4.

By Carl Danzig, MD, Diana V. Do, MD

ELARA Data Support Monthly Aflibercept 8 mg in Refractory nAMD and DME

Dilsher S. Dhoot, MD, FASRS, presents ELARA findings in previously treated patients with neovascular AMD and diabetic macular edema.

By Dilsher S. Dhoot, MD, Diana V. Do, MD

Can ROP Be Prevented?

The phase 1b tROPhy-1 study is evaluating FLQ-101, an investigational therapy designed to intervene before severe disease develops.

By Jim Gallagher, senior managing editor

In RVO, Aflibercept 8 mg Outcomes Unaffected by Baseline CRT

A post hoc analysis of QUASAR data, presented at Clinical Trials at the Summit, finds consistent visual and anatomic results across retinal vein occlusion subtypes.

By Jim Gallagher, senior managing editor

NEW DAY: Sustained-Release Steroid vs Anti-VEGF Therapy

Michael A. Singer, MD, presents data comparing a sustained-release fluocinolone acetonide implant with aflibercept in patients with retinal vascular disease.

By Michael A. Singer, MD, Diana V. Do, MD

Real-World Findings Reinforce Encelto’s Role in MacTel Treatment

Roger A. Goldberg, MD, MBA, shared early postapproval experience with Encelto, including an evolving surgical technique, at Clinical Trials at the Summit.

By Jim Gallagher, senior managing editor

A Potential First Treatment for Stargardt Disease

Data from the phase 3 DRAGON trial support tinlarebant as a treatment for the inherited retinal disorder. Belite Bio has completed a rolling NDA submission to the FDA.

By Quan Dong Nguyen, MD, Diana V. Do, MD

OLN-324 Shows Extended Drying in DME

In the JADE trial, the investigational bispecific agent demonstrated a faster and more durable anatomic response than faricimab. Phase 3 trials are expected to begin later this year.

By Margaret Chang, MD, Diana V. Do, MD

New Therapy Combines Wnt Activation and VEGF Inhibition

SZN-8141 is designed to activate Wnt signaling while inhibiting VEGF, bringing 2 therapeutic mechanisms into a single molecule.

By Daniel Chao, MD, Diana V. Do, MD

Five-Year Insights From the Pegcetacoplan Program

Lawrence J. Singerman, MD, FACS, reflects on clinical insights from the OAKS, DERBY, and GALE studies in geographic atrophy.

By Lawrence J. Singerman, MD, FACS, Diana V. Do, MD

Biogen Signals Long-Term Commitment to Retina

At Clinical Trials at the Summit, industry veteran Anthony Wallace discussed how collaboration between biotech companies, pharmaceutical firms, and retina specialists drives innovation.

By Jim Gallagher, senior managing editor

Getting Started in Clinical Trials

Deepak Sambhara, MD, FASRS, says aspiring investigators should seek mentorship, build relationships, and stay curious as they pursue opportunities in clinical research.

By Deepak Sambhara, MD, FASRS , Diana V. Do, MD

Migaldendranib Shows Substantial Injection Reduction

Early phase 2 data in DME and nAMD showed approximately 80% reduction in intravitreal injection burden compared with pre-study treatment.

By Michael A. Singer, MD, Diana V. Do, MD